Australia’s Propanc Biopharma has secured up to $100 million from Hexstone Capital to build a crypto treasury supporting its cancer treatment research. The private placement includes $1 million upfront and $99 million over 12 months.
CEO James Nathanielsz said the move strengthens the firm’s balance sheet and funds trials for its lead therapy, PRP, set for human testing in 2026. Hexstone clients invest across Bitcoin, Ether, Solana, and Injective. Propanc joins a growing list of biotech firms adopting crypto treasuries to attract investors.
You need to login in order to Like
Leave a comment